Alumis Inc.(ALMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALMS Alumis Inc.

Post-Market Trading 03-31 18:47:55 EDT

6.14

+0.50

+8.87%

盘后6.12

-0.02-0.33%

18:37 EDT

High6.14	Low5.07	Vol696.11K
Open5.65	D1 Closing5.64	Amplitude18.94%
Mkt Cap334.06M	Tradable Cap122.50M	Total Shares54.41M
T/O3.98M	T/O Rate3.49%	Tradable Shares19.95M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":6.14,"timestamp":1743451200000,"preClose":5.64,"halted":0,"volume":696114,"hourTrading":{"tag":"盘后","latestPrice":6.12,"preClose":6.14,"latestTime":"18:37 EDT","volume":3170,"amount":19177.3271,"timestamp":1743460662926},"delay":0,"floatShares":19951689,"shares":54407327,"eps":-15.598233,"marketStatus":"Post-Market Trading","change":0.5,"latestTime":"03-31 18:47:55 EDT","open":5.65,"high":6.14,"low":5.0717,"amount":3981111.0501456005,"amplitude":0.189415,"askPrice":6.15,"askSize":1,"bidPrice":5.29,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-15.598233,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743465600000},"marketStatusCode":4,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":5.64,"preHourTrading":{"tag":"盘前","latestPrice":5.65,"preClose":5.64,"latestTime":"09:29 EDT","volume":11534,"amount":64702.7826824,"timestamp":1743427790589},"postHourTrading":{"tag":"盘后","latestPrice":6.12,"preClose":6.14,"latestTime":"18:37 EDT","volume":3170,"amount":19177.3271,"timestamp":1743460662926},"volumeRatio":0.163043},"requestUrl":"/m/hq/s/ALMS/wiki","defaultTab":"wiki","newsList":[{"id":"2522390295","title":"Alumis Inc. Reports 2024 Results and Strategic Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2522390295","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522390295?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 12:00","pubTimestamp":1743048049,"startTime":"0","endTime":"0","summary":"Alumis Inc. ( ($ALMS) ) has released its Q4 earnings. Here is a breakdown of the information Alumis Inc. presented to its investors. Alumis Inc. is...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alumis-inc-reports-2024-results-and-strategic-merger?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alumis-inc-reports-2024-results-and-strategic-merger?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2522820870","title":"Alumis Price Target Maintained With a $15.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522820870","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522820870?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 18:54","pubTimestamp":1742986440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 06:54 ET (10:54 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2522885443","title":"Sector Update: Health Care Stocks Decline Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2522885443","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522885443?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 01:56","pubTimestamp":1742925375,"startTime":"0","endTime":"0","summary":"Health care stocks were falling Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund  each down about 1.1%.The iShares Biotechnology ETF  fell 1.4%.In corporate news, 23andMe's  customers were asked by New York Attorney General Letitia James to take action for protection of their data as the company goes through bankruptcy, the state prosecutor's office said in a consumer alert Tuesday. 23andMe shares were falling past 13%.Merck  secured exclusive global rights to develop and sell China-based Jiangsu Hengrui Pharmaceuticals' heart disease drug in a deal worth up to about $2 billion. Merck shares were down 4.1%.Alumis  shares rose past 7% after the company and Kaken Pharmaceutical said they signed a collaboration and licensing agreement to develop, manufacture, and commercialize ESK-001 for dermatology indications in Japan, with an option to expand the license to include rheumatological and gastrointestinal diseases.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999013999.USD","LU2468319806.SGD","SG9999002232.USD","LU1917777945.USD","LU1061106388.HKD","LU1093756168.USD","LU0861579265.USD","LU1934455863.HKD","IE00BSNM7G36.USD","LU1037948541.HKD","LU1983299246.USD","LU0211331839.USD","LU0203345920.USD","XLV","MRK","IBB","ME","IE0002141913.USD","LU0289739699.SGD","SG9999001176.SGD","LU2089984988.USD","LU1571399168.USD","LU1941712264.USD","LU2023250843.SGD","SG9999014542.SGD","LU1116320901.HKD","LU1116320737.USD","LU0985320562.USD","SG9999001176.USD","LU1069347547.HKD","IE00B2B36J28.USD","BK4534","LU0320765489.SGD","SG9999015358.SGD","SG9999014567.USD","LU0122379950.USD","IE000M9KFDE8.USD","BK4516","LU1066051498.USD","BK4588","LU1035773651.USD","ALMS","LU2112291526.USD","LU0203347892.USD","LU0238689110.USD","MEHCQ","LU1989771016.USD","LU2106854487.HKD","LU0106261372.USD","LU2361044949.HKD","IE00BN8TJ469.HKD"],"gpt_icon":0},{"id":"2522009493","title":"BUZZ-Alumis jumps on licensing deal for skin drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522009493","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522009493?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 23:25","pubTimestamp":1742916325,"startTime":"0","endTime":"0","summary":"BUZZ-Alumis jumps on licensing deal for skin drug** Shares of biopharmaceutical firm Alumis ALMS.O rise 15.5% to $4.36, hitting over one-month high** ALMS and Tokyo-based Kaken Pharmaceutical 4521.T say they have entered into a licensing agreement to develop, manufacture and commercialize an experimental skin drug in Japan** ALMS' lead drug candidate, ESK-001, is currently in a late-stage study which aims to fix immune system issues in various diseases caused by inflammatory substances like IL-23, IL-17, and type 1 interferon** ALMS will receive $40 million in upfront and near-term co-development payments in 2025 to 2026** The company could earn up to $140 million more based on milestone achievements** ESK-001 is also being tested in a mid-stage study to treat a type of autoimmune disease called systemic lupus erythematosus** ALMS has fallen 44.4% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL6N3Q80KT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2522006287","title":"Alumis Shares Rise on Licensing Agreement with Japanese Drug Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2522006287","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522006287?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 23:12","pubTimestamp":1742915520,"startTime":"0","endTime":"0","summary":"Alumis shares rose after the company signed a licensing agreement, worth $40 million in the short-term, with Tokyo-based Kaken Pharmaceutical.The stock climbed 17.9% to $4.45 on Tuesday, recovering some of the loss over the past few days that brought the stock to a 52-week low on Friday. Shares are down 43% this year.The San Francisco biotechnology company said Tuesday it entered a collaboration and licensing agreement to develop, manufacture and commercialize ESK-001, an oral tyrosine kinase 2 inhibitor.The treatment is designed for dermatology use in Japan, but could be expanded to include rheumatological and gastrointestinal diseases. It uses proinflammatory mediators to correct immune dysregulation across several diseases.Alumis is set to receive $40 million for immediate co-development payments in 2025 and 2026. It has the potential to earn up to $140 million in additional payments based on field option payments and reaching milestones.Alumis is also eligible to receive tiered roy","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Alumis Shares Rise on Licensing Agreement with Japanese Drug Company","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2522074761","title":"Alumis Shares up 26.5% After Licensing Agreement With Kaken Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2522074761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522074761?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 21:34","pubTimestamp":1742909677,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q81EL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2522075351","title":"Alumis Shares Jump 67.4% Premarket After Licensing Agreement With Kaken Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2522075351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522075351?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:46","pubTimestamp":1742906791,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL3N3Q80V5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2522209730","title":"Alumis, Kaken Pharmaceutical Enter Collaboration, Licensing Deal for Dermatology Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522209730","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522209730?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 16:28","pubTimestamp":1742891285,"startTime":"0","endTime":"0","summary":"Alumis  and Kaken Pharmaceutical have struck a collaboration and licensing agreement to develop, manufacture and commercialize ESK-001 for dermatology indications in Japan, with an option to expand the license to include rheumatological and gastrointestinal diseases, the companies said Tuesday.Under the terms of the agreement, Alumis will receive $40 million in upfront and near-term co-development payments this year and next year, with the potential to earn up to approximately $140 million in additional milestone payments, the companies said.Alumis is also eligible to receive tiered royalties ranging from the low double-digits into the twenties on total Japanese net sales of ESK-001, the companies said.Kaken will be responsible for the clinical development, regulatory approvals and commercialization of ESK-001 in Japan and contribute toward global development costs of the drug, the companies said.The drug is currently being evaluated in a phase 3 clinical trial for patients with modera","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2522091486","title":"BRIEF-Alumis And Kaken Pharmaceutical Announce Collaboration And Licensing Agreement For ESK-001 In Dermatology In Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2522091486","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522091486?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 16:03","pubTimestamp":1742889810,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis And Kaken Pharmaceutical Announce Collaboration And Licensing Agreement For ESK-001 In Dermatology In JapanMarch 25 (Reuters) - Alumis Inc ALMS.O:ALUMIS AND KAKEN PHARMACEUTICAL ANNOUNCE ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUABZHV5J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2522627780","title":"Positive Buy Rating for Alumis Inc. Driven by Promising TYK2 Inhibitors and Strategic Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2522627780","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522627780?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 14:45","pubTimestamp":1742885156,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith maintained a Buy rating on Alumis Inc. (ALMS – Research Report) yesterday and set a price target of $29.00. T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-buy-rating-for-alumis-inc-driven-by-promising-tyk2-inhibitors-and-strategic-advancements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-buy-rating-for-alumis-inc-driven-by-promising-tyk2-inhibitors-and-strategic-advancements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"gpt_icon":0},{"id":"2522064446","title":"Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for Esk-001 in Dermatology in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2522064446","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522064446?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 14:30","pubTimestamp":1742884200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUABZHV5J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2522064091","title":"Alumis Inc - to Receive $40 Million Upfront, Potential $140 Million in Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2522064091","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522064091?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 14:30","pubTimestamp":1742884200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUABZHV5J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2521972300","title":"Semtech Expands Anterix-Compatible Solutions for Utility Infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2521972300","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521972300?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"AirLink XR60 5G Router Now Supports Anterix’s 900 MHz Private Spectrum for Mission-Critical Energy Networks. The ultra-rugged AirLink XR60 5G router delivers versatile, high-performance connectivity, tailored to the demanding needs of utility networks. Supporting both commercial networks and global private LTE and 5G standalone  bands, it now operates on Anterix’s spectrum, standardized under 3GPP Release 18 as band 106. This advancement positions the XR60 as a pivotal tool in driving the adoption of private networks within the utility sector.\"Anterix is thrilled to build on our collaboration with Semtech, a member of the 125+ solutions providers within the Anterix Active Ecosystem. Semtech’s efforts help to expand the reach of our 900MHz private broadband spectrum technology for utilities,\" said Steve Ryan, vice president, ecosystem and partnerships at Anterix. \"With this collaboration, utilities gain access to game-changing solutions purpose-built for secure and resilient operations ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/semtech-expands-anterix-compatible-solutions-120000501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4141","BK4007","SMTC","BK4089","ALMS","BK4588","BK4585","BK4017","ATEX"],"gpt_icon":0},{"id":"2520473455","title":"Oppenheimer Sticks to Their Buy Rating for Alumis Inc. (ALMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520473455","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520473455?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 20:16","pubTimestamp":1742472975,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Jeff Jones reiterated a Buy rating on Alumis Inc. (ALMS – Research Report) today and set a price target of $26.00. The company’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-alumis-inc-alms?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-alumis-inc-alms?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","ALMS"],"gpt_icon":0},{"id":"2520434194","title":"Alumis Price Target Cut to $15.00/Share From $19.00 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2520434194","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520434194?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 18:31","pubTimestamp":1742466660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 06:31 ET (10:31 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2520434873","title":"Alumis Inc : H.c. Wainwright Cuts Target Price to $15 From $19","url":"https://stock-news.laohu8.com/highlight/detail?id=2520434873","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520434873?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 18:23","pubTimestamp":1742466210,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q30MB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2520431796","title":"Alumis price target lowered to $15 from $19 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2520431796","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520431796?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 18:10","pubTimestamp":1742465439,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Alumis (ALMS) to $15 from $19 and keeps a Buy rating on the shares following the Q4 report. The ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-price-target-lowered-to-15-from-19-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-price-target-lowered-to-15-from-19-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"gpt_icon":0},{"id":"2520019878","title":"Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2520019878","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520019878?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 04:05","pubTimestamp":1742414701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA7CCKHR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2520933601","title":"Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2520933601","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520933601?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 04:05","pubTimestamp":1742414700,"startTime":"0","endTime":"0","summary":"– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated;","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/19/3045800/0/en/Alumis-Reports-Year-End-2024-Financial-Results-and-Highlights-Recent-Achievements.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU2111349929.HKD","LU1548497426.USD","BK4588","BK4007","LU2089284900.SGD","LU1989772840.SGD","LU2133065610.SGD","LU0225283273.USD","LU0912757837.SGD","LU0314104364.USD","LU1989772923.USD","BK4127","BK4504","LU1720051108.HKD","SLE","BK4077","LU0006306889.USD","LU2271345857.HKD","BK4516","LU2028103732.USD","LU2089283258.USD","LU2347655156.SGD","LU2023251221.USD","BK4585","LU0106261372.USD","LU0106831901.USD","LU0795875086.SGD","LU0098860793.USD","BK4135","LU0795875169.SGD","LU2357305700.SGD","ALMS","LU0158827948.USD","LU0320765646.SGD","LU0971096721.USD","LU1720051017.SGD","LU1162221912.USD","LU1074936037.SGD","CNS","LU0158827781.USD","LU1732799900.SGD","LU1732800096.USD","IE00BKVL7J92.USD","LU0267386448.USD","LU1363072403.SGD","IE00BZ1G4Q59.USD","BK4534","LU1668664300.SGD"],"gpt_icon":0},{"id":"2519350938","title":"Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2519350938","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519350938?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 20:15","pubTimestamp":1741868100,"startTime":"0","endTime":"0","summary":"Acelyrin said its board approved adopting a limited-duration shareholders' rights plan in response to Tang Capital Partners' accumulation of a stake in the company.The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock.Acelyrin said Tang Capital held 8.8% of its outstanding common stock.Tang Capital didn't immediately respond to a request for comment issued through LinkedIn.Poison pills, also called shareholder-rights plans, are legal maneuvers that make it hard for shareholders to build their stakes beyond a set point by triggering an option for others to buy more shares at a discount.Acelyrin in February received an unsolicited indication of interest from Concentra Biosciences, a portfolio company under Tang Capital Management, for an acquisition at","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SLRN","ALMS","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alumis.com","stockEarnings":[{"period":"1week","weight":0.504},{"period":"1month","weight":0.2341},{"period":"3month","weight":-0.3002},{"period":"6month","weight":-0.4946},{"period":"1year","weight":-0.6475},{"period":"ytd","weight":-0.2824}],"compareEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0654},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.0277},{"period":"1year","weight":0.0623},{"period":"ytd","weight":-0.0519}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Alumis Inc.","nameEN":"Alumis Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alumis Inc.(ALMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alumis Inc.(ALMS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alumis Inc.,ALMS,Alumis Inc.股票,Alumis Inc.股票老虎,Alumis Inc.股票老虎国际,Alumis Inc.行情,Alumis Inc.股票行情,Alumis Inc.股价,Alumis Inc.股市,Alumis Inc.股票价格,Alumis Inc.股票交易,Alumis Inc.股票购买,Alumis Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alumis Inc.(ALMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alumis Inc.(ALMS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}